Date: 26 June 2003 ELAN CORPORATION, PLC. AND WATSON LABORATORIES, INC. AMENDED AND RESTATED LICENCE AND SUPPLY AGREEMENT (VERAPAMIL)Licence and Supply Agreement • August 14th, 2015 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
In the event that Elan acquires or merges with a third party entity, Elan Know-How shall not include any know-how to the extent that such know-how relates to a product containing the same active ingredient as the DSDF which has been approved for marketing or is in development by the said third party entity at the time of such acquisition or merger. For the avoidance of doubt, the occurrence of any such acquisition or merger shall not affect the license of the Elan Know-How granted to Watson hereunder.
SUPPLEMENTAL AGREEMENTSupplemental Agreement • August 14th, 2015 • Recro Pharma, Inc. • Pharmaceutical preparations
SUPPLEMENTAL AGREEMENT NO. 2 TO THE AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT (GENERIC VERAPAMIL)Supplemental Agreement • August 14th, 2015 • Recro Pharma, Inc. • Pharmaceutical preparations
This Supplemental Agreement No. 2 to the Amended and Restated License and Supply Agreement (Generic Verapamil) (“Supplemental Agreement No. 2”) is made the 17th day of January 2014 (“Supplemental Agreement No. 2 Effective Date”).
DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT BETWEEN ALKERMES PHARMA IRELAND LIMITED AND RECRO PHARMA, INC.Manufacturing and Supply Agreement • August 14th, 2015 • Recro Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of July 10, 2015 (the “Effective Date”) by and between Alkermes Pharma Ireland Limited, a private limited company organized and existing under the laws of the Republic of Ireland (“Alkermes”), and Recro Pharma, Inc., a corporation organized and existing under the laws of Pennsylvania (“Recro”). Recro and Alkermes are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
